Exelixis, Inc. $EXEL Shares Sold by Applied Finance Capital Management LLC

Applied Finance Capital Management LLC lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 6.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,856 shares of the biotechnology company’s stock after selling 505 shares during the quarter. Applied Finance Capital Management LLC’s holdings in Exelixis were worth $302,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Byrne Asset Management LLC boosted its holdings in Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new position in Exelixis in the second quarter worth $33,000. Hemington Wealth Management boosted its holdings in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 522 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new position in Exelixis in the first quarter worth $37,000. Finally, Steph & Co. acquired a new position in Exelixis in the second quarter worth $44,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of research reports. Stephens raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Truist Financial reduced their price target on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, July 29th. Stifel Nicolaus boosted their price target on shares of Exelixis from $38.00 to $41.00 and gave the company a “hold” rating in a report on Tuesday, July 29th. Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Morgan Stanley boosted their price target on shares of Exelixis from $46.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 17th. Fifteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Stock Up 0.1%

EXEL stock opened at $39.25 on Friday. The company has a market capitalization of $10.57 billion, a P/E ratio of 18.87, a PEG ratio of 0.79 and a beta of 0.38. The company has a 50-day simple moving average of $38.82 and a 200 day simple moving average of $40.02. Exelixis, Inc. has a fifty-two week low of $27.86 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Equities analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.